MitraClip in Asia　― Current Adoption and Regional Data ―

Abstract

almost all Asian countries (except Japan) affects the rate of uptake. Second, regulatory approvals take time and effort to obtain. Furthermore, some countries such as Japan and China require local trials before approval for use. Third, the conservative nature of Asian societies, both patients and physicians, may make adoption of relatively newer technologies a slower process. The first MitraClip procedure in the Asia-Pacific was performed at Sir Charles Gairdner Hospital, Australia, on 23 March 2011, while the first in Asia was performed soon after at the National Heart Centre Singapore on 14 April 2011 (Table 1). 19 This paved the way for other Asian countries to open their MitraClip programs. The most recent country to start the MitraClip program is Japan, which received regulatory approval for the MitraClip in 2017 and subsequently national reimbursement in 2018. This was only after completion of the Japanese AVJ-514 trial, which provided the regulatory authorities with the requisite data for approval of the use of the device. 20 Once the MitraClip was approved in Japan, the accompanying reimbursement allowed for rapid adoption of the therapy. Figure shows the gradual increase in MitraClip cases over the years for each region, with an exponential jump last year with the introduction of Japan. MitraClip Data in Asia Limited data on MitraClip therapy have been published in Asia (Table 2), 20-23 as compared with the extensive global experience and literature. The MitraClip Asia-Pacific Registry (MARS) is a multinational , multi-center registry started in February 2011 in an effort to describe the MitraClip experience in the Asia-Pacific region. Thus far, 17 centers from 10 countries (Australia,

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

“…SEA indicates Southeast Asia (Singapore, Malaysia, Indonesia, Brunei, Philippines, Vietnam, Thailand). Source: Data derived from Wong et al 92…”

“…Use of MitraClip procedures has also increased in Asia, although at a slower pace (Chart 23-2), with the highest increase seen in Japan from 18 procedures in 2011 to 439 procedures in 2018. 92…”

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

“…Use of MitraClip procedures has also increased in Asia, although at a slower pace (Chart 23-4), with the highest increase seen in Japan from 18 procedures in 2011 to 439 procedures in 2018. 112…”

Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation

“…Surgical mitral valve repair or replacement is still the gold standard for DMR, although transcatheter therapy may have a role in the management of a subset of patients. [ 7 , 8 , 14 , 15 ] Data from MARS found that the acute procedural success rate for patients with DMR was 92%. [ 3 ] The 30-day major adverse event rate was 14.7%, which was not significantly different from FMR patients (9.2%; p=0.555).…”

“…However, published data on the use of the MitraClip among Asian populations are limited compared with the West. [ 7 ] The multicentre retrospective MARS registry, involving eight sites in five Asia-Pacific countries, reported the early experience in Asia with 142 patients who underwent the MitraClip procedure from February 2011 to October 2013. In this study, the acute procedural success rate was 93.7%.…”